Last reviewed · How we verify

NCT03335878: NewT

Brain Health and Development With T1DM

Completed Last updated 11 April 2024
What this trial tests

trial in T1DM in 290 participants. Completed in 6 December 2021.

Timeline
1 September 2016
Primary endpoint
6 December 2021
6 December 2021

Quick facts

Lead sponsorWashington University School of Medicine
StatusCompleted
Study typeOBSERVATIONAL
Enrollment290
Start date1 September 2016
Primary completion6 December 2021
Estimated completion6 December 2021
Sites1 location across United States

Conditions studied

Sponsor

Washington University School of Medicine

Who can join

Adults 4 to 16, any sex, with T1DM or Brain Development. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Type 1 diabetes mellitus (T1DM) is typically diagnosed in childhood and over time can lead to complications affecting the retina, heart, kidneys, peripheral nerves, and more recently appreciated, the brain. Studies consistently find that early age of onset and, to a more variable extent, poor glycemic control over years are associated with reduced cognitive performance and altered brain structure in children with T1DM. As yet, the investigators' understanding of why early age of onset would pose more risks for the brain is limited, making interventions difficult to develop. Given that the initial clinical presentation of T1DM in children is the earliest and often the most severe glycemic state experienced over the lifetime, it is possible that age of onset and severity of initial clinical presentation interact to modify risks for brain health and development. This hypothesis has clear clinical implications and the potential to resolve conflicting literature, yet has not been explicitly tested. Thus, the goal of this study is to determine how clinical features at the time of T1DM diagnosis, such as hyperglycemia, diabetic ketoacidosis (DKA) and degree of beta cell failure, interact with age of onset to shape the development of the brain and its responses to subsequent glycemic control.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Neurofilament light chain but not glial fibrillary acidic protein serum levels are elevated in Wolfram syndrome.
    Jansen MJ, Lugar HM, Brown CM, Tang AF, et al · · 2026 · PMID 41929703 · DOI 10.3389/fnins.2026.1805916

Verify or expand the search:

Other recruiting trials for T1DM

Currently open trials in the same condition.

Other Washington University School of Medicine trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03335878.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing